Vitruvias Recalls 1,955 Thyroid Tablets Nationwide Over Superpotency Risk

3 articles · Updated · NBC Chicago · Aug 25

Lot 504950 of Vitruvias' 30 mg Thyroid Tablets was pulled nationwide after the company said the pills could be superpotent and trigger hyperthyroidism instead of treating hypothyroidism.
1,955 units were sold from 3,655 released, with distribution running from Jan. 31, 2025, to Sept. 30, 2025; wholesalers are being told to stop distribution and the tablets will be destroyed.
Patients were told not to stop taking the prescription drug without consulting a doctor, even as the FDA notice warned of heat intolerance, chest pain, rapid heart rate and rhythm disturbances.
Elderly and pregnant patients face the highest risk because excess thyroid hormone can cause cardiac problems and maternal-fetal complications, though Vitruvias said no adverse events have been reported.
The recall follows another recent thyroid-drug pull involving subpotent levothyroxine sodium tablets, underscoring broader quality concerns in this medication category.